Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) has granted an inducement restricted stock unit award to a new non-executive employee. The award, approved on August 5, 2024, covers 3,500 shares of Puma common stock. This grant falls under Puma's 2017 Employment Inducement Incentive Award Plan, adopted on April 27, 2017. The award will vest over three years, with one-third vesting on August 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This award is in compliance with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for the new employee to join Puma.
Puma Biotechnology (NASDAQ: PBYI) ha concesso un un nuovo dipendente non esecutivo. Questo premio, approvato il 5 agosto 2024, copre 3.500 azioni di azioni ordinarie di Puma. Questo riconoscimento rientra nel Piano di Incentivazione all'Occupazione del 2017 di Puma, adottato il 27 aprile 2017. Il premio si sboccerà in tre anni, con un terzo che si sboccerà il 1° agosto 2025, e un sesto che si sboccerà ogni sei mesi successivamente, a condizione di continuare a essere impiegato. Questo premio è conforme alla Regola di quotazione Nasdaq 5635(c)(4) e serve come incentivo per il nuovo dipendente per unirsi a Puma.
Puma Biotechnology (NASDAQ: PBYI) ha otorgado un premio de unidad de acciones restringidas por incentivo a un nuevo empleado no ejecutivo. El premio, aprobado el 5 de agosto de 2024, cubre 3,500 acciones de acciones ordinarias de Puma. Este otorgamiento se encuentra bajo el Plan de Incentivos por Empleo 2017 de Puma, adoptado el 27 de abril de 2017. El premio se otorgará en tres años, con un tercio otorgándose el 1 de agosto de 2025, y un sexto cada seis meses después, dependiendo de la continuidad del empleo. Este premio cumple con la Regla de Cotización 5635(c)(4) de Nasdaq y sirve como un incentivo para que el nuevo empleado se una a Puma.
Puma Biotechnology (NASDAQ: PBYI)는 새로운 비임원 직원에게 유도 제한 주식 단위 보상을 부여했습니다. 이 보상은 2024년 8월 5일에 승인되었으며, 3,500주의 Puma 보통주를 포함합니다. 이 보상은 2017년 4월 27일에 채택된 Puma의 2017 고용 유도 인센티브 보상 계획에 해당합니다. 이 보상은 3년 동안 단계적으로 제공됩니다, 2025년 8월 1일에 1/3이 부여되며, 이후 매 6개월마다 1/6이 부여되며, 계속 고용되어 있는 경우에 해당합니다. 이 보상은 Nasdaq 상장 규정 5635(c)(4)를 준수하며, 새로운 직원이 Puma에 합류하도록 유도하는 역할을 합니다.
Puma Biotechnology (NASDAQ: PBYI) a accordé une attribution d'unités d'actions restreintes pour incitation à un nouvel employé non exécutif. Cette attribution, approuvée le 5 août 2024, couvre 3 500 actions de l'action ordinaire de Puma. Cette attribution relève du Plan d'Incentive d'Emploi de 2017 de Puma, adopté le 27 avril 2017. L'attribution s'accomplira sur une période de trois ans, avec un tiers se réalisant le 1er août 2025, et un sixième tous les six mois par la suite, sous réserve d'un emploi continu. Cette attribution est conforme à la règle d'inscription Nasdaq 5635(c)(4) et sert d'incitation pour le nouvel employé à rejoindre Puma.
Puma Biotechnology (NASDAQ: PBYI) hat einem neuen nicht-executive Mitarbeiter eine verleihene eingeschränkte Beteiligung an Aktien gegeben. Diese Auszeichnung, die am 5. August 2024 genehmigt wurde, umfasst 3.500 Aktien gewöhnlicher Aktien von Puma. Diese Vergabe fällt unter den 2017 eingeführten Anreizplan von Puma, der am 27. April 2017 verabschiedet wurde. Die Auszeichnung wird über drei Jahre gewährt, wobei ein Drittel am 1. August 2025 und ein Sechstel alle sechs Monate danach gewährt wird, vorausgesetzt, dass das Arbeitsverhältnis fortbesteht. Diese Auszeichnung entspricht der Nasdaq-Notierungsregel 5635(c)(4) und dient als Anreiz für den neuen Mitarbeiter, zu Puma zu kommen.
- Attracting new talent with equity-based compensation
- Compliance with Nasdaq listing rules for inducement awards
- Potential dilution of existing shareholders' equity
The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, August 1, 2024, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806146216/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
What type of award did Puma Biotechnology (PBYI) grant on August 5, 2024?
How does the vesting schedule work for Puma Biotechnology's (PBYI) recent stock award?
Under which plan was Puma Biotechnology's (PBYI) recent stock award granted?
What is the purpose of Puma Biotechnology's (PBYI) inducement award?
